Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H10N6O.C6H8O7 |
| Molecular Weight | 374.3067 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)\N=N\C1=C(N=CN1)C(N)=O.OC(=O)CC(O)(CC(O)=O)C(O)=O
InChI
InChIKey=UKLSKIDEWQXQJZ-ASTDGNLGSA-N
InChI=1S/C6H10N6O.C6H8O7/c1-12(2)11-10-6-4(5(7)13)8-3-9-6;7-3(8)1-6(13,5(11)12)2-4(9)10/h3H,1-2H3,(H2,7,13)(H,8,9);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b11-10+;
| Molecular Formula | C6H10N6O |
| Molecular Weight | 182.1832 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
| Molecular Formula | C6H8O7 |
| Molecular Weight | 192.1235 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Dacarbazine (DTIC), also known as imidazole carboxamide, is an antineoplastic agent, which is used in the treatment of metastatic malignant melanoma. In addition, this drug also is indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents. Dacarbazine works by methylating guanine at the O-6 and N-7 positions. Guanine is one of the four nucleotides that makes up DNA. The alkylated DNA strands stick together such that cell division becomes impossible. This affects cancer cells more than healthy cells because cancer cells divide faster. Dacarbazine is bioactivated in liver by demethylation to "MTIC" and then to diazomethane, which is an alkylating agent. Symptoms of anorexia, nausea, and vomiting are the most frequently noted of all toxic reactions. Over 90% of patients are affected with the initial few doses.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2311221 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | DTIC-DOME Approved UseDacarbazine for Injection USP is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection USP is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents. Launch Date1.70380804E11 |
|||
| Primary | DTIC-DOME Approved UseDacarbazine for Injection USP is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection USP is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents. Launch Date1.70380804E11 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.2 μg/mL |
750 mg/m² single, intravenous dose: 750 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
DACARBAZINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14.8 μM × min |
750 mg/m² single, intravenous dose: 750 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
DACARBAZINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
41.4 min |
750 mg/m² single, intravenous dose: 750 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
DACARBAZINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
95% |
DACARBAZINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1000 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 1000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 1 times / 3 weeks Co-administed with:: Lenalidomide, p.o(5 mg/day; 14 days) Sources: Page: p.503, 504 |
unhealthy, 34–79 n = 3 Health Status: unhealthy Condition: Malignant melanoma Age Group: 34–79 Sex: M+F Population Size: 3 Sources: Page: p.503, 504 |
Disc. AE: Cerebral ischemia... AEs leading to discontinuation/dose reduction: Cerebral ischemia (grade 4, 33%) Sources: Page: p.503, 504 |
800 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 800 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 1 times / 3 weeks Co-administed with:: Lenalidomide, p.o(5 mg/day; 14 days) Sources: Page: p.503 |
unhealthy, 34–79 n = 16 Health Status: unhealthy Condition: Malignant melanoma Age Group: 34–79 Sex: M+F Population Size: 16 Sources: Page: p.503 |
DLT: Thrombocytopenia... Disc. AE: Thrombocytopenia... Dose limiting toxicities: Thrombocytopenia (grade 2, 6.25%) AEs leading todiscontinuation/dose reduction: Thrombocytopenia (grade 1, 6.25%) Sources: Page: p.503 |
1000 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 1000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 1 times / 3 weeks Sources: Page: p.5 |
unhealthy, 40–65 n = 45 Health Status: unhealthy Condition: Malignant melanoma Age Group: 40–65 Sex: M+F Population Size: 45 Sources: Page: p.5 |
Other AEs: Neutropenia, Fatigue... Other AEs: Neutropenia (grade 4, 2.2%) Sources: Page: p.5Fatigue (grade 4, 2.2%) |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Disc. AE: Leukopenia, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Leukopenia (grade 3-5) Sources: Thrombocytopenia (grade 3-5) Anemia (sometimes) Hematopoiesis impaired Hepatotoxicity (grade 3-5, 0.01%) Hepatic vein thrombosis (grade 3-5, 0.01%) Necrosis hepatocellular (grade 3-5, 0.01%) Anaphylaxis |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Disc. AE: Anemia, Leukopenia... AEs leading to discontinuation/dose reduction: Anemia (mild) Sources: Leukopenia (grade 3-5) Thrombocytopenia (grade 3-5) Hepatotoxicity (grade 3-5) Hepatic vein thrombosis (grade 3-5) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Cerebral ischemia | grade 4, 33% Disc. AE |
1000 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 1000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 1 times / 3 weeks Co-administed with:: Lenalidomide, p.o(5 mg/day; 14 days) Sources: Page: p.503, 504 |
unhealthy, 34–79 n = 3 Health Status: unhealthy Condition: Malignant melanoma Age Group: 34–79 Sex: M+F Population Size: 3 Sources: Page: p.503, 504 |
| Thrombocytopenia | grade 1, 6.25% Disc. AE |
800 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 800 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 1 times / 3 weeks Co-administed with:: Lenalidomide, p.o(5 mg/day; 14 days) Sources: Page: p.503 |
unhealthy, 34–79 n = 16 Health Status: unhealthy Condition: Malignant melanoma Age Group: 34–79 Sex: M+F Population Size: 16 Sources: Page: p.503 |
| Thrombocytopenia | grade 2, 6.25% DLT |
800 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 800 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 800 mg/m2, 1 times / 3 weeks Co-administed with:: Lenalidomide, p.o(5 mg/day; 14 days) Sources: Page: p.503 |
unhealthy, 34–79 n = 16 Health Status: unhealthy Condition: Malignant melanoma Age Group: 34–79 Sex: M+F Population Size: 16 Sources: Page: p.503 |
| Fatigue | grade 4, 2.2% | 1000 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 1000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 1 times / 3 weeks Sources: Page: p.5 |
unhealthy, 40–65 n = 45 Health Status: unhealthy Condition: Malignant melanoma Age Group: 40–65 Sex: M+F Population Size: 45 Sources: Page: p.5 |
| Neutropenia | grade 4, 2.2% | 1000 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 1000 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 1000 mg/m2, 1 times / 3 weeks Sources: Page: p.5 |
unhealthy, 40–65 n = 45 Health Status: unhealthy Condition: Malignant melanoma Age Group: 40–65 Sex: M+F Population Size: 45 Sources: Page: p.5 |
| Anaphylaxis | Disc. AE | 250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Hematopoiesis impaired | Disc. AE | 250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Hepatic vein thrombosis | grade 3-5, 0.01% Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Hepatotoxicity | grade 3-5, 0.01% Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Necrosis hepatocellular | grade 3-5, 0.01% Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Leukopenia | grade 3-5 Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Thrombocytopenia | grade 3-5 Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Anemia | sometimes Disc. AE |
250 mg/m2 1 times / day multiple, intravenous Recommended Dose: 250 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Hepatic vein thrombosis | grade 3-5 Disc. AE |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Hepatotoxicity | grade 3-5 Disc. AE |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Leukopenia | grade 3-5 Disc. AE |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Thrombocytopenia | grade 3-5 Disc. AE |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
| Anemia | mild Disc. AE |
850 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 850 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 850 mg/m2, 1 times / 3 weeks Sources: |
unhealthy Health Status: unhealthy Condition: Malignant melanoma Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: 2195.0 |
no | |||
Page: 2195.0 |
no | |||
Page: abstract |
yes | |||
Page: abstract |
yes | |||
Page: abstract |
yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin. | 1975 Nov |
|
| [DTIC: effect on fibrinolysis and thrombocyte function]. | 1986 Oct |
|
| Fatal hepatic vascular toxicity of DTIC. Is it really a rare event? | 1988 May 15 |
|
| Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication. | 1989 May |
|
| Inhibition of melanoma growth and metastasis by combination with (-)-epigallocatechin-3-gallate and dacarbazine in mice. | 2001 |
|
| Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation. | 2001 Dec |
|
| [Correlation between functional capability and phenotypic characteristics of peripheral blood lymphocytes in patients with malignant melanoma]. | 2002 |
|
| Docetaxel in combination with dacarbazine in patients with advanced melanoma. | 2002 |
|
| Phase II trial of Paclitaxel and Dacarbazine with filgrastim administration in advanced malignant melanoma. | 2002 |
|
| Successful palliation of stenosing anorectal melanoma by intratumoral injections with natural interferon-beta. | 2002 Aug |
|
| Analysis of O(6)-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy. | 2002 Aug |
|
| Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha. | 2002 Dec |
|
| The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine. | 2002 Feb |
|
| Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer. | 2003 Feb 20 |
|
| Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo. | 2003 Jan |
|
| Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma. | 2003 Jan 13 |
|
| [Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma]. | 2004 |
|
| A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. | 2004 Dec |
|
| Serum bcl-2 and survivin levels in melanoma. | 2004 Dec |
|
| Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. | 2004 Dec |
|
| Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma. | 2004 Jun |
|
| Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. | 2004 Jun 1 |
|
| Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model. | 2005 Aug |
|
| Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. | 2005 Dec |
|
| Artesunate in the treatment of metastatic uveal melanoma--first experiences. | 2005 Dec |
|
| Deficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents through G2-M cell cycle arrest. | 2005 Jun |
|
| Functional erythropoietin autocrine loop in melanoma. | 2005 Mar |
|
| A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity. | 2005 Oct |
|
| Sarcomatoid renal cell carcinoma with a chromophobe component producing beta-human chorionic gonadotropin. | 2005 Sep |
|
| Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial. | 2006 |
|
| Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study. | 2006 Aug-Sep |
|
| Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in a mouse melanoma model. | 2006 Dec |
|
| Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group. | 2006 Nov |
|
| Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. | 2006 Oct 10 |
|
| Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. | 2007 |
|
| Single-agent interleukin-2 in the treatment of metastatic melanoma. | 2007 Feb |
|
| Resection in the popliteal fossa for metastatic melanoma. | 2007 Jan 19 |
|
| Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group. | 2007 Jul |
|
| Hemorrhagic cystitis in a patient receiving conventional doses of dacarbazine for metastatic malignant melanoma: case report and review of the literature. | 2007 Jun |
|
| Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. | 2007 Jun |
|
| CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma. | 2007 Nov |
|
| Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast. | 2007 Nov-Dec |
|
| Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. | 2007 Oct |
|
| Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice. | 2007 Oct |
|
| Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. | 2007 Sep 1 |
|
| The management of desmoids in patients with familial adenomatous polyposis (FAP). | 2008 |
|
| Hodgkin lymphoma presenting with various immunologic abnormalities, including autoimmune hepatitis, Hashimoto's thyroiditis, autoimmune hemolytic anemia, and immune thrombocytopenia. | 2008 Feb |
|
| Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. | 2008 Mar |
|
| Unexpected clinical outcome in a patient with liver and brain metastasis from melanoma. | 2008 Mar-Apr |
|
| A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | 2014 Jan |
Patents
Sample Use Guides
Malignant Melanoma: the recommended dosage is 2 to 4.5 mg/kg/day for 10 days. Treatment may be repeated at 4 week intervals
Hodgkin's Disease: The recommended dosage of Dacarbazine for Injection, USP in the treatment of Hodgkin’s disease is 150 mg/square meter body surface/day for 5 days, in combination with other effective drugs. Treatment may be repeated every 4 weeks.5 An alternative recommended dosage is 375 mg/square meter body surface on day 1, in combination with other effective drugs, to be repeated every 15 days
Route of Administration:
Intravenous
The effect of alkyating agent dacarbazine (DTIC) and imexon, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). Growth inhibition in vitro was additive with the two drugs. There was no effect on drug uptake or on the number of DNA strand breaks. There was a >75% reduction in cellular glutathione and cysteine with imexon but not DTIC. Co-administration of the two drugs in mice caused an increase in the area under the curve of both drugs, but the combination was not effective in reducing human A375 melanoma tumors in vivo.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 17 17:49:36 UTC 2022
by
admin
on
Sat Dec 17 17:49:36 UTC 2022
|
| Record UNII |
9UYU348NIF
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB01547MIG
Created by
admin on Sat Dec 17 17:49:36 UTC 2022 , Edited by admin on Sat Dec 17 17:49:36 UTC 2022
|
PRIMARY | |||
|
9UYU348NIF
Created by
admin on Sat Dec 17 17:49:36 UTC 2022 , Edited by admin on Sat Dec 17 17:49:36 UTC 2022
|
PRIMARY | |||
|
64038-56-8
Created by
admin on Sat Dec 17 17:49:36 UTC 2022 , Edited by admin on Sat Dec 17 17:49:36 UTC 2022
|
PRIMARY | |||
|
135565662
Created by
admin on Sat Dec 17 17:49:36 UTC 2022 , Edited by admin on Sat Dec 17 17:49:36 UTC 2022
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |